In one study, median OS was 9.7 months (95% CI, 9.1–10.3) for patients initiating first-line therapy in 2012–2015, thus before ICI approvals in the US, for stage IV NSCLC with no documented EGFR or ALK genomic alterations, not restricted to those with good performance status (8). The gene discussed is ALK; the disease is non-small cell lung carcinoma.